HC Wainwright Reaffirms “Buy” Rating for IN8bio (NASDAQ:INAB)

HC Wainwright restated their buy rating on shares of IN8bio (NASDAQ:INAB) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $8.00 price target on the stock.

IN8bio Stock Up 2.9 %

INAB opened at $0.30 on Tuesday. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.05. The stock’s fifty day simple moving average is $0.30 and its 200 day simple moving average is $0.63. IN8bio has a 1-year low of $0.22 and a 1-year high of $2.48. The stock has a market cap of $22.08 million, a PE ratio of -0.41 and a beta of -0.07.

IN8bio (NASDAQ:INAB) last posted its earnings results on Tuesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, research analysts expect that IN8bio will post -0.56 earnings per share for the current year.

Hedge Funds Weigh In On IN8bio

An institutional investor recently raised its position in IN8bio stock. Sigma Planning Corp lifted its holdings in shares of IN8bio, Inc. (NASDAQ:INAB) by 42.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 851,280 shares of the company’s stock after purchasing an additional 251,600 shares during the quarter. Sigma Planning Corp owned 1.82% of IN8bio worth $230,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.